Bicycle Therapeutics (NASDAQ:BCYC) Given New $15.00 Price Target at Needham & Company LLC

Bicycle Therapeutics (NASDAQ:BCYC) had its price objective lowered by Needham & Company LLC from $24.00 to $15.00 in a research report released on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd. Truist Financial set a $8.00 price target on shares of Bicycle Therapeutics in a research note on Tuesday. Morgan Stanley reissued a “sell” rating and issued a $13.00 price target on shares of Bicycle Therapeutics in a research report on Tuesday. Finally, Jefferies Financial Group upgraded shares of Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $14.50.

Bicycle Therapeutics Stock Performance

Shares of NASDAQ BCYC opened at $4.70 on Wednesday. The stock’s 50-day simple moving average is $5.87 and its 200-day simple moving average is $6.79. The firm has a market capitalization of $326.04 million, a PE ratio of -1.49 and a beta of 1.65. Bicycle Therapeutics has a fifty-two week low of $4.59 and a fifty-two week high of $9.94.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its quarterly earnings results on Tuesday, March 17th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.71. The firm had revenue of $47.96 million during the quarter, compared to the consensus estimate of $7.08 million. Bicycle Therapeutics had a negative return on equity of 32.40% and a negative net margin of 301.66%. On average, sell-side analysts forecast that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Alethia Young sold 4,334 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the sale, the chief financial officer owned 87,081 shares in the company, valued at approximately $565,155.69. This trade represents a 4.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Lee sold 10,989 shares of Bicycle Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the sale, the chief executive officer directly owned 618,996 shares in the company, valued at approximately $3,998,714.16. The trade was a 1.74% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 38,029 shares of company stock valued at $251,966. 22.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Fcpm Iii Services B.V. raised its stake in shares of Bicycle Therapeutics by 0.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,468,430 shares of the company’s stock worth $24,556,000 after buying an additional 16,100 shares in the last quarter. Armistice Capital LLC grew its holdings in Bicycle Therapeutics by 8.7% during the fourth quarter. Armistice Capital LLC now owns 3,236,000 shares of the company’s stock worth $22,911,000 after acquiring an additional 258,000 shares during the period. Westfield Capital Management Co. LP raised its position in Bicycle Therapeutics by 2.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 3,016,026 shares of the company’s stock worth $21,353,000 after acquiring an additional 63,483 shares in the last quarter. GSK plc acquired a new stake in Bicycle Therapeutics in the fourth quarter valued at $10,829,000. Finally, Long Focus Capital Management LLC boosted its position in shares of Bicycle Therapeutics by 7.7% during the 3rd quarter. Long Focus Capital Management LLC now owns 1,418,695 shares of the company’s stock worth $10,981,000 after purchasing an additional 101,402 shares in the last quarter. Institutional investors and hedge funds own 86.15% of the company’s stock.

Key Bicycle Therapeutics News

Here are the key news stories impacting Bicycle Therapeutics this week:

• Positive Sentiment: Q4 results materially beat expectations — Bicycle reported EPS of ($0.29) vs. consensus ($1.00) and revenue of $47.95M vs. $7.08M, a large topline surprise that supports the company’s commercial progress and clinical outlook. Read More.
• Neutral Sentiment: Short‑interest reports show a “large increase” flagged for March but list zero shares and NaN changes; the short‑interest ratio is reported as 0.0 days — this appears to be a reporting/data anomaly and is unlikely to be a meaningful driver while figures remain inconsistent.
• Negative Sentiment: Oppenheimer cut its price target from $44 to $36 but kept an “outperform” rating — a notable reduction in upside that can weigh on sentiment. Read More.
• Negative Sentiment: Royal Bank of Canada lowered its target from $11 to $7 and moved to “sector perform” — another downward revision that reduces analyst‑implied valuation. Read More.
• Negative Sentiment: Citizens Jmp trimmed its target from $12 to $8 while maintaining “market outperform” — a cut that may temper near‑term enthusiasm. Read More.
• Negative Sentiment: Needham lowered its target from $24 to $15 but kept a “buy” rating — another sizable reduction in analyst upside that could pressure the stock despite the buy rating. Read More.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.